Study shows pharmacists knew more about penicillin allergy than MDs

If you have gone through life avoiding certain antibiotics because you think you're allergic to penicillin, you'd probably want to know if you're not actually allergic. A new study shows many physicians who treat patients with "penicillin allergy" listed in their charts may not fully understand important facts about penicillin allergy. They may not be aware penicillin allergy can resolve over time and they don't fully understand the importance of allergy testing to make sure a penicillin allergy currently exists.

The study in Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology (ACAAI) examined 276 surveys completed by non-allergist physicians, physician assistants, nurse practitioners and pharmacists at Rochester Regional Health. They found more than 80 percent of the general practitioners surveyed in their system knew a referral to an allergist for testing is appropriate for someone with a reported penicillin allergy. Despite that, the physicians had either never referred their patients to an allergist, or had only done so with one patient a year. In addition, pharmacists surveyed in their system had a better overall understanding of penicillin allergy.

"We were not surprised pharmacists understood the course of penicillin allergy better than other clinicians, given more extensive pharmacology education," says infectious diseases pharmacist Mary Staicu, PharmD, lead author of the study. "Of those surveyed, 78 percent of pharmacists knew penicillin allergy can resolve over time. Only 55 percent of the remaining respondents (non-allergist physicians, physician assistants and nurse practitioners) did." The survey also showed a limited understanding among internists and general practitioners regarding the large numbers of people who report penicillin allergy but have never been tested." Most of the physicians surveyed had been in practice more than 10 years.

Between 10-20 percent of Americans believe they have a penicillin allergy. But previous research has found only 10 percent of those people are truly penicillin allergic. In other words, 9 out of 10 people who think they have penicillin allergy are avoiding it for no reason. Even in people with documented allergy to penicillin, only about 20 percent are still allergic ten years after their initial allergic reaction.

"Our research found a poor understanding of penicillin allergy among non-allergists," says allergist Allison Ramsey, MD, study co-author and ACAAI member. "This was not a surprising finding given the clinical experience of most allergists, but it does provide an excellent opportunity for education on the topic - not just for patients, but for all health care professionals."

People who are labeled penicillin allergic are often prescribed second-line antibiotics, which may have a higher risk of side effects and increased cost. "More than 90 percent of people labeled with a penicillin allergy can tolerate penicillin-based antibiotics," says Dr. Ramsey. "Our survey showed only 30 percent of physician survey respondents knew that. It's important that doctors understand the importance of confirming penicillin allergy. But it's even more important that those who carry the label be educated and tested."

An allergist can work with you to find out if you have a true drug allergy and determine what antibiotics are available for safe and effective treatment. If you're not allergic, you'll be able to safely use antibiotics that are often more effective, and less expensive.

Staicu ML, Soni D, Conn KM, Ramsey A.
A survey of inpatient practitioner knowledge of penicillin allergy at 2 community teaching hospitals.
Ann Allergy Asthma Immunol. 2017 May 20. pii: S1081-1206(17)30339-3. doi: 10.1016/j.anai.2017.04.023.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]